Immunic(US:IMUX) Prnewswireยท2025-09-09 10:30Core Insights - Immunic, Inc. has received a Notice of Allowance for a new patent related to vidofludimus calcium, which is aimed at treating progressive multiple sclerosis (PMS) and is expected to provide protection until 2041, with potential extensions [1][2] Group 1: Patent and Intellectual Property - The newly allowed patent covers dose strengths of vidofludimus calcium ranging from 10 mg to 45 mg for treating PMS, including primary and secondary progressive forms [1] - Immunic's intellectual property strategy includes multiple granted patents in the U.S. and Europe, covering various aspects of vidofludimus calcium, including composition-of-matter and dosing regimens [2] - A pending application could extend patent protection for vidofludimus calcium up to 2044 if granted, with additional undisclosed applications in process to strengthen exclusivity [2] Group 2: Clinical Development and Efficacy - Vidofludimus calcium has shown neuroprotective potential in clinical trials, delaying confirmed disability worsening and reducing brain volume loss in patients with PMS [2][3] - The drug is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [4] - To date, vidofludimus calcium has been tested in approximately 2,700 individuals, demonstrating a favorable pharmacokinetic, safety, and tolerability profile [3]